Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)
NCT ID: NCT04731701
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2021-05-05
2022-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GAS-Hem Feasibility Study
NCT02674997
Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy
NCT05187936
Pain and Joint Status With Psychosocial Factors in Patients With Hemophilia
NCT04715100
The Second Multicenter Hemophilia Cohort Study
NCT00341705
Gait Examination in Patients With Hemophilia in Austria
NCT03541811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hemophilia Joint Health Score (HJHS)
Joint examination with Hemophilia Joint Health Score (HJHS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of haemophilia A or B.
3. Capable of completing the study Patient-Reported Outcome (PRO) questionnaires in French.
4. Signed informed consent.
Exclusion Criteria
1. Joint replacement within last 6 months.
2. Patients with a non-resolved joint or muscle bleeding event at the enrolment visit or ≤ 7 days prior to the enrolment visit.
3. Patients with comorbid illnesses such as juvenile arthritis, muscular dystrophy, neurologic illness/cognitive impairment, or other illnesses that may independently affect HJHS and Hemo-FAST scores and/or limit the ability of the patient to participate in the study as determined by the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kantar Health
INDUSTRY
Cerner Enviza (former Kantar Health)
UNKNOWN
Swedish Orphan Biovitrum
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Physician
Role: STUDY_DIRECTOR
Swedish Orphan Biovitrum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swedish Orphan Biovitrum Clinical site
Paris, Cochin, France
Swedish Orphan Biovitrum Clinical site
Paris, Kremlin-Bicêtre, France
Swedish Orphan Biovitrum Clinical site
Besançon, , France
Swedish Orphan Biovitrum Clinical site
Bordeaux, , France
Swedish Orphan Biovitrum Clinical site
Brest, , France
Swedish Orphan Biovitrum Clinical site
Caen, , France
Swedish Orphan Biovitrum Clinical site
Clermont-Ferrand, , France
Swedish Orphan Biovitrum Clinical site
Dijon, , France
Swedish Orphan Biovitrum Clinical site
Lyon, , France
Swedish Orphan Biovitrum Clinical site
Marseille, , France
Swedish Orphan Biovitrum Clinical site
Nancy, , France
Swedish Orphan Biovitrum Clinical site
Nantes, , France
Swedish Orphan Biovitrum Clinical site
Rouen, , France
Swedish Orphan Biovitrum Clinical site
Saint-Etienne, , France
Swedish Orphan Biovitrum Clinical site
Strasbourg, , France
Swedish Orphan Biovitrum Clinical site
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sobi.HAEM89-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.